← Back to Search

Anti-biotic

Calcium Sulfate Antibiotic Depot for Open Tibia Fractures

Phase 3
Recruiting
Led By Jessica Rivera, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 6, month 3, month 6 and month12
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is studying if a new treatment can better prevent infection in people with lower leg fractures.

Who is the study for?
Adults over 18 with a Type II or III open tibia fracture needing an intramedullary nail can join. Excluded are those under 18, allergic to vancomycin/tobramycin, with high blood calcium levels, without contact info, prisoners, non-English/Spanish speakers, and pregnant or breastfeeding women.
What is being tested?
The trial is testing if using calcium sulfate mixed with antibiotics (vancomycin hydrochloride or gentamicin) inside the bone is better at preventing infections compared to the usual treatment in patients with severe lower leg fractures.
What are the potential side effects?
Possible side effects include allergic reactions to antibiotics used (vancomycin/gentamicin), issues related to high calcium levels due to the calcium sulfate depot and typical risks associated with surgery such as pain and infection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 6, month 3, month 6 and month12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 6, month 3, month 6 and month12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants who develop deep surgical site infection (SSI)
Secondary study objectives
Average Time to Return to Work/Duty
International Physical Activity Questionnaire (IPAQ)
Number of Participants who Return to the Operating Room (OR)
+18 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Standard of care intramedullary nail (SN)Experimental Treatment1 Intervention
Standard of care intramedullary nail
Group II: Intramedullary calcium sulfate antibiotic depot prior to Intramedullary nailing (IMN) placement (CS)Experimental Treatment2 Interventions
The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gentamicin
2015
Completed Phase 4
~1160

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,403 Previous Clinical Trials
2,477,838 Total Patients Enrolled
Jessica Rivera, MDPrincipal InvestigatorLouisiana State University Health Science Center
Rachel B Seymour, PhDPrincipal InvestigatorWake Forest University Health Sciences

Media Library

Intramedullary Calcium Sulfate Antibiotic Depot (Anti-biotic) Clinical Trial Eligibility Overview. Trial Name: NCT05766670 — Phase 3
Tibial Fracture Research Study Groups: Standard of care intramedullary nail (SN), Intramedullary calcium sulfate antibiotic depot prior to Intramedullary nailing (IMN) placement (CS)
Tibial Fracture Clinical Trial 2023: Intramedullary Calcium Sulfate Antibiotic Depot Highlights & Side Effects. Trial Name: NCT05766670 — Phase 3
Intramedullary Calcium Sulfate Antibiotic Depot (Anti-biotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05766670 — Phase 3
~331 spots leftby Jan 2027